valsartan + lisinopril

**Valsartan + lisinopril** is a combination of two antihypertensive agents: valsartan, an angiotensin II receptor blocker (ARB), and lisinopril, an angiotensin-converting enzyme (ACE) inhibitor. This combination is not available as a single branded product but has been studied for synergistic effects in reducing blood pressure and albuminuria in patients with hypertension and microalbuminuria. Valsartan blocks the binding of angiotensin II to its receptor, leading to vasodilation and reduced aldosterone production, while lisinopril prevents the formation of angiotensin II from angiotensin I, also leading to vasodilation. Used together, they may offer increased benefits in renoprotection and normalization of microalbuminuria compared to monotherapy, but the combination is rarely used in clinical practice due to safety concerns regarding dual blockade of the renin-angiotensin system and increased risk of adverse effects, including hypotension, kidney dysfunction, and hyperkalemia[1][6].